Progressive Pulmonary Fibrosis (PPF) - Epidemiology Forecast - 2032

This ‘Progressive pulmonary fibrosis (PPF)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Progressive pulmonary fibrosis (PPF), historical and forecasted epidemiology as well as the PPF trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Progressive pulmonary fibrosis (PPF) Disease Understanding

Progressive pulmonary fibrosis (PPF) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.

Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.

Progressive pulmonary fibrosis (PPF) are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs.

Progressive pulmonary fibrosis (PPF) Diagnosis

Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), is key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive pulmonary fibrosis (PPF) is calculated on the basis of FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.

The differential diagnosis of Interstitial Lung Diseases requires a multidisciplinary approach, usually involving pulmonologist, radiologist, and pathologist. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging and if required, lung biopsy.

Progressive pulmonary fibrosis (PPF) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of ILD, Type-specific Diagnosed Prevalent Cases of ILD, and Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF), in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2019 to 2032.

Progressive pulmonary fibrosis (PPF) Detailed Epidemiology Segmentation

• In the assessment done by the publisher, the estimated total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in the 7MM were 127,754 in 2021.
• The highest total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) were accounted by the US in 2021 (71,657 cases), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of PPF with 11,115 cases, followed by the United Kingdom, which had prevalent population of 9,872 in 2021. On the other hand, Spain had the lowest prevalent population (6,401 cases).
• Japan had 10,296 total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in 2021, accounting for approximately 8% in 7MM.

Scope of the Report

• The report covers the descriptive overview of Progressive pulmonary fibrosis (PPF), explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Progressive pulmonary fibrosis (PPF).
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights

• 11-Year Forecast of Progressive pulmonary fibrosis (PPF)
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF)

Key Questions Answered

• What are the disease risk and burden of Progressive pulmonary fibrosis (PPF)?
• What is the historical Progressive pulmonary fibrosis (PPF) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Progressive pulmonary fibrosis (PPF) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Progressive pulmonary fibrosis (PPF)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Progressive pulmonary fibrosis (PPF) during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Progressive pulmonary fibrosis (PPF) report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM+ Progressive pulmonary fibrosis (PPF) epidemiology forecast.
• The Progressive pulmonary fibrosis (PPF) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Progressive pulmonary fibrosis (PPF) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032